Drug Discovery News Covers GATC’s PNAS Breakthrough, Extending Media Momentum Around GATC-1021

Recent coverage in Drug Discovery News reinforces continued external interest in GATC’s AI-enabled discovery platform and the therapeutic promise of its non-opioid OUD candidate

Irvine, CA — May 5, 2026 — GATC Health is pleased to share additional media momentum stemming from the company’s recent PNAS publication on GATC-1021, its AI-derived non-opioid drug candidate for opioid use disorder. In a recent feature, Drug Discovery News, a premier industry authority bridging academic breakthroughs and commercial drug development highlighted the program in an article titled, “AI-designed drug cuts fentanyl intake and reshapes brain circuits in preclinical study,” describing GATC-1021 as a compound that reduced opioid intake in rats and was linked to changes in synaptic organization and gene expression in reward-related brain regions.

The continuing interest generated by this paper signals that the market is interested in the immediate findings on GATC-1021, as well as AI’s ability to design differentiated therapeutics in areas of major unmet need.

As reported in the underlying PNAS paper, GATC-1021 emerged from an AI-guided process that started with human-derived data and culminated in a candidate that significantly reduced fentanyl intake in both male and female rats, while also modulating neuroplasticity-related biology and avoiding hallucinogenic-like effects in preclinical testing. Those elements have become central to the external narrative because they help distinguish the program as more than a general “AI in drug discovery” story. Instead, they position it as a concrete example of AI being used to identify a candidate with a compelling mechanistic rationale, measurable behavioral effects, and a differentiated profile in a difficult therapeutic area.